跳至主要内容
临床试验/NL-OMON53440
NL-OMON53440招募中不适用

FDG-PET/CT to reduce the need for sentinel lymph node biopsy in early-stage oral cancer. - PETN0

niversitair Medisch Centrum Utrecht0 个研究点目标入组 159 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
159

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • To be eligible to participate in this study, a subject must meet all of the
  • following criteria:
  • Newly diagnosed early-stage OSCC is defined as clinically T1-3, N0 (only when
  • T3 is assessed based on tumor dimensions of >2 cm and <=4 cm with DOI >10 mm)
  • The patient is >=18 years of age at the time of consent.
  • The patient has no palpable lymph nodes in the neck.
  • Clinical nodal staging (cN0) has been confirmed by ultrasound, CT, and/or MRI
  • if performed (not mandatory).
  • The patient is a candidate for transoral excision and SLNB.
  • The patient has provided written informed consent authorization before
  • participating in the study.

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • The patient has other pathologies than squamous cell carcinoma;
  • The patient has recurrent primary oral squamous cell carcinoma;
  • The patient has a history of treatment of the neck (neck dissection and/or
  • radiotherapy);
  • The patient has ultrasound guided fine needle aspiration cytology positive
  • for lymph node metastasis;
  • The patient has poorly controlled diabetes mellitus;
  • The patient refused preoperative imaging workups.
  • A potential subject who meets the following criteria will only be excluded for
  • the contrast-enhanced CT of the head and neck:
  • The patient has had a previous allergic reaction after administration of
  • contrast fluid.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验

FDG-PET/CT to reduce the need for sentinel lymph... | 临床试验